Treatment Results of Low-Grade Gliomas in Children (a Retrospective Data Analysis)

Czech version

Authors: Z. Pavelka ¹; K. Zitterbart ¹; T. Pavlík ²; P. Šlampa ³; J. Ventruba ⁴; E. Brichtová ⁴; M. Smrčka ⁵; T. Paleček ⁶; J. Jakubec ⁷; M. Houdek ⁸; L. Křen ⁹; J. Skotáková ¹⁰; H. Ošlejšková ¹¹; T. Turbová ¹; J. Štěrba ¹
Authors‘ workplace: Klinika dětské onkologie LF MU a FN Brno – PDM ¹; Institut biostatistiky a analýz PřF MU a LF MU Brno ²; Klinika radiační onkologie, Masarykův onkologický ústav, Brno ³; Neurochirurgické oddělení, KDCHaT LF MU a FN Brno – PDM ⁴; Neurochirurgická klinika LF MU a FN Brno – PMDV ⁵; Neurochirurgická klinika FNsP Ostrava ⁶; Neurochirurgická klinika LF UK a FN Hradec Králové ⁷; Neurochirurgická klinika LF UP a FN Olomouc ⁸; Ústav patologie LF MU a FN Brno – PMDV ⁹; Klinika dětské radiologie LF MU a FN Brno – PDM ¹⁰; Klinika dětské neurologie LF MU a FN Brno – PDM ¹¹
Published in: Cesk Slov Neurol N 2008; 71/104(2): 206-214
Category: Short Communication

Overview

Children with low-grade gliomas (except brain stem gliomas) have good prognosis, 80–90 % of them are long time survivors. Their optimal management is influenced by the anatomical location of the tumour and the patient age. We present the retrospective analysis of 108 children treated in our institution between 1998 and 2006 years according to SIOP CNS 9702 study. The median age at diagnosis was 5.5 years with the prevalence of boys (58,3 %). Histological types distribution were follows: pilocytic astrocytoma (46,3 %), fibrillary astrocytoma (20,4 %), oligodendroglioma (5,6 %). In the whole cohort 5-year overall survival (OS5) was 96,2 %, 5-year event-free survival (EFS5) was 83,8 %. In the gross total resection group EFS was 90 %, median EFS for incomplete surgery was 77,4 months (p = 0,007). Unfavourable localizations represent diencephalon, metastatic spread and more structures affected, with median EFS of 78,8 months (p = 0,005). 36 children were treated with chemotherapy with EFS of 6 0%, and PFS of 50 %. Only 4 children have died, 3 of them from progression or relapse. We have proven 2 significant factors influencing outcome: extent of resection and tumor localization. Chemotherapy allows the delay of radiotherapy in a certain proportion of children. The risk subgroup, for which new therapeutic options are needed, are mainly inoperable tumors of diencephalon.

Key words:
children – low-grade gliomas – chemotherapy – radiotherapy – prognostic factors

Sources

1. Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst 2001; 17(9): 503–511.

2. Gupta N, Banerjee A, Hass-Kogan D. Pediatric CNS tumors. Berlin: Springer 2004.

3. Kleihues P, Cavanee WK. Pathology and genetics of tumors of the nervous system. Lyon: International Agency for Research on Cancer (IARC) Press 2000.

4. Walker DA, Perilongo G, Punt JA, Taylor RE. Brain and spinal tumors of childhood. London: A Hodder Arnold Publication 2004.

5. Campbell JW, Pollack IF. Cerebellar astrocytomas in children. J Neurooncol 1996; 28(2–3): 223–231.

6. Viano JC, Herrera EJ, Suárez JC. Cerebellar astrocytomas: a 24-year experience. Childs Nerv Syst 2001; 17(10): 607–610.

7. Packer RJ. Chemotherapy: low-grade gliomas of the hypothalamus and thalamus. Pediatr Neurosurg 2000; 32(5): 259–263.

8. Mahoney DH jr, Cohen ME, Friedman HS, Kepner JL, Gemer L, Langston JW et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro Oncol 2000; 2(4): 213–220.

9. Kortmann RD, Timmermann B, Taylor RE, Scarzello G, Plasswilm L, Paulsen F et al. Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part I: Treatment modalities of radiation therapy. Strahlenther Onkol 2003; 179(8): 509–520.

10. Kortmann RD, Timmermann B, Taylor RE, Scarzello G, Plasswilm L, Paulsen F et al. Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II: Treatment related late toxicity. Strahlenther Onkol 2003; 179(9): 585–597.

11. Kaye AH, Walker DG. Low grade astrocytomas: controversies in management. J Clin Neurosci 2000; 7(6): 475–483.

12. Massimino M, Spreafico F, Cefalo F, Riccardi R, Tesoro-Tess JD, Gandola L et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol 2002; 20(20): 4209–4216.

13. Walker DA, Gnekow AK, Perilongo G, Zanetti I. Vincristine (VCR), carboplatin (CBDCA) in hypothalamic-chiasmatic glioma (HCG): a report of the international consortium on low grade glioma (ICLGG). Med Ped Oncol 2002; 39: 229.

14. Gnekow AK, Kaatsch P, Kortmann R, Wiestler OD. HIT-LGG: effectivenes of carboplatin-vincristine in progressive low-grade gliomas of childhood – an interim report. Klin Padiatr 2000; 212(4): 177–184.

15. Galanis E, Buckner JC, Maurer MJ, Sykora R, Castillo R, Ballman KV et al. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro Oncol 2006; 8(2): 156–165.

16. Broome CB, Schiff RI, Friedman HS. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol 1996; 26(2): 105–110.

17. Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 1993; 11(5): 850–856.

18. Walker DA. Recent advances in optic nerve glioma with a focus on the young patient. Curr Opin Neurol 2003; 16(6): 657– 664.

19. Gajjar A, Bhargava R, Jenkins JJ, Heideman R, Sanford RA, Langston JW et al. Low grade astrocytoma with neuraxis dissemination at diagnosis. J Neurosurg 1995; 83(1): 67–71.

20. Pollack IF, Boyett JM, Yates AJ, Burger PC, Gilles FH, Davis RL et al. The influence of central review on outcome associations on childhood malignant gliomas: results from the CCG-945 experience. Neuro Oncol 2003; 5(3): 197–207.

21. Listernick R, Charrow J, Greenwald M, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994; 125(1): 63–66.

22. Pollack IF, Mulvihill JJ. Special issues in the management of gliomas in children with neurofibromatosis 1. J Neurooncol 1996; 28(2–3): 257–268.

23. Torp SH. Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies. Clin Neuropathol 2002; 21(6): 252–257.

24. Streffer J, Schabet M, Bamberg M, Grote EH, Meyermann R, Voigt K et al. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J Neurol 2000; 247(4): 297–302.

25. Feigenberg SJ, Amdur RJ, Morris CG, Mendehall WM, Marcus RB jr, Friedman WA. Oligodendroglioma: does deferring treatment compromise outcome? Am J Clin Oncol 2003; 26(3): 60–66.

26. Wernicke C, Thiel G, Lozanova T, Vogel S, Witkowski R. Numerical aberrations of chromosomes 1, 2 and 7 in astrocytomas studied by interphase cytogenetics. Genes Chromosomes Cancer 1997; 19(1): 6–13.

27. Kramář F, Zemanová Z, Michalová K, Babická L, Ransdorfová Š, Kozler P et al. Patogeneze mozkových gliomů, I. část. Úvod do problematiky, patogeneze astrocytárních nádorů. Cesk Slov Neurol N 2006; 69/102(5): 346–54.

28. Childrensoncologygroup.[online]. URL: <http://members.childrensoncologygroup.org/prot>.

29. Gajjar A, Sanford RA, Heideman R, Jenkins JJ, Walter A, Li Y et al. Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital. J Clin Oncol 1997; 15(8): 2792–2799.

30. Whittle IR. Surgery for gliomas. Curr Opin Neurol 2002; 15(6): 663–669.

31. Kortmann RD. Radiotherapy in low-grade gliomas: pros. Semin Oncol 2003; 30(Suppl 19): 29–

32. Gururangan S, Cavazos CM, Ashley D, Herndon JE, Bruggers CS, Moghrabi A et al. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol 2002; 20(13): 2951–2958.

33. International Society of Paediatric Oncology [online]. c2000. Dostupné z <http://www.siop.nl>.

34. Chamberlain MC, Grafe MR. Reccurent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol 1995; 13(8): 2072–2076.

35. Khaw SL, Coleman LT, Downie PA, Heath JA, Ashley DM. Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer 2007; 49(6): 808–11.

36. Stiver SI. Angiogenesis and its role in the behavior of astrocytic brain tumors. Front Biosci 2004; 9: 3105–3123.

37. McLaughlin ME, Robson CD, Kieran MW, Jacks T, Pomeroy SL, Cameron S. Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. J Pediatr Hematol Oncol 2003; 25(8): 644–648.